ABNewswire - Press Release Distribution Service

Saturday, August 24, 2019

Schneider Electric India announced kick-starting its innovation challenge ‘Hackware 2019’ in India

Schneider Electric invites participants to present their bold ideas around the areas impacting sectors of urban, residential, buildings and industry

Schneider Electric India announced kick-starting its innovation challenge ‘Hackware 2019’ in India. The contest will offer an open platform for seasoned experts as well as budding engineers to share ideas that can reshape the future and showcase the criticality of sustainability. Built around the three themes – Decarbonization, Decentralization and Digitization of EcoStruxure.

The 72 hours hackathon will include Masterclasses on technology, innovation, design thinking and keynote by experts. Teams will be selected during the hackathon to make their presentations to an esteemed jury for the selection of winners. Registration for the contest can be done on the following link: Hackware.se.com

Schneider Electric believes the ideas generated through the event will help build better “Buildings of the Future”, “Plants of the Future”, “Grids of the Future” and ensure the creation of a secure and sustainable energy system driven by energy-efficient solutions!

As a leader in the Digital Transformation of Energy Management and Automation, Schneider Electric is strategically positioned across the entire energy landscape. It is consistently on the lookout for bold ideas that can shape the industry and the organisation’s future.

About Schneider Electric

Schneider Electric is leading the Digital Transformation of Energy Management and Automation in Homes, Buildings, Data Centers, Infrastructure and Industries. With global presence in over 100 countries, Schneider is the undisputable leader in Power Management - Medium Voltage, Low Voltage and Secure Power, and in Automation Systems. We provide integrated efficiency solutions, combining energy, automation and software. In our global Ecosystem, we collaborate with the largest Partner, Integrator and Developer Community on our Open Platform to deliver real-time control and operational efficiency. We believe that great people and partners make Schneider a great company and that our commitment to Innovation, Diversity and Sustainability ensures that Life Is On everywhere, for everyone and at every moment.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email:Send Email
Phone: 8745857610
Country: India
Website: https://www.schneider-electric.co.in/en/

Schneider Electric launched the Altivar™ Process 6000 (ATV6000) medium voltage service-oriented drive

• ATV6000 improves process performance and asset management capabilities so businesses can achieve up to a 20% productivity increase and 20% downtime reduction

• Real time information and key performance indicators offer new level of operation insight for enhanced energy management to reduce consumptions and increase savings

• New medium voltage offer broadens the extensive line of Altivar variable speed drives

Schneider Electric, the leader of digital transformation in energy management and automation, today launched the Altivar™ Process 6000 (ATV6000) medium voltage service-oriented drive. The ATV6000 is a smart, connected product that can help optimize businesses by enabling process optimization, improving energy management, enhancing asset management and providing a tailored engineering solution. Schneider Electric is currently working with UL and expect to have a listing by December, 2019.

Equipped with Schneider Electric's EcoStruxure™ Asset Advisor, the ATV6000 provides a unique solution to optimize the operation and maintenance of installations. It allows businesses to plug into the Industrial Internet of Things to manage maintenance tasks on assets with preventive and predictive management based on real-time assessments and predictive analytics.

"Our customers are focused on reducing energy consumption and operating costs, while still meeting their production goals," said Garrett Abbott-Frey, US Enclosed Senior Drive Offer Manager, Schneider Electric. "Connected solutions like the Altivar Process 6000 offer sustainable efficiency without adding additional costs so users can monitor energy usage and optimize their overall operation."

The Schneider Electric ATV6000 with EcoStruxure Asset Advisor transforms data into insights to help run operations more efficiently and safer, with greater availability and increased profits. As part of EcoStruxure, Schneider Electric's IIoT-enabled, plug-and-play, open, interoperable architecture and platform architecture, this service-oriented drive delivers greater energy management through smart data collection, real time performance information and lifetime energy monitoring to reduce consumption.

The Schneider Electric ATV6000 provides a high level of customization to meet specific purposes, offering flexibility for modifications and extensions. This means that no matter the challenge, electrical or mechanical, Schneider Electric's application specialists and design engineers will provide optimized solutions resulting in Capex and Opex savings.

The digital capabilities and mechanical characteristics of the ATV6000 also ensure improved operator efficiency, fast and easy onsite maintenance operations, easy troubleshooting with dynamic QR codes and comfortable usability with the 10" Magelis HMI. While the ATV6000's modular architecture and easy front access design, provides simple parts replacement, quicker maintenance, and minimized spare part stock references.

About Schneider Electric

Schneider Electric has embarked on a robotic process automation journey, establishing a global team to evaluate RPA use cases

Schneider Electric, a multinational energy management company, has embarked on a robotic process automation journey, establishing a global team to evaluate RPA use cases.

A robotic process automation rollout in the energy management sector shows even an ambitious RPA journey begins with some small steps.

Schneider Electric is a large enterprise. The company, headquartered in France, generated €25.7 billion (about $28.5 billion) in 2018 revenue, employs 130,000 people and does business in more than 100 countries. Elizabeth Hackenson, CIO at Schneider Electric, said the company's RPA efforts got underway in earnest in mid-2018. Pilot projects paved the way for a global initiative in 2019. "What we like to do with new technology such as this is just go into a couple of pilots," she said. "Those pilots were successful, so what we did early this year was create a global team."

Schneider Electric's business spans a range of fields, including IoT, building automation, industrial automation, and data center infrastructure such as cooling and power distribution systems. The company's stated goal is the "digital transformation of energy management and automation."

Where the bots are

Schneider Electric's RPA journey is now part of that transformative vision. The company's initial pilots paved the way for the 170 bots in production as of July 1. The majority of those RPA instances -- a bit more than 100 -- are in China.

"They have been more advanced," Hackenson said of the Chinese RPA adopters, citing a regional CIO who was able to rapidly identify use cases and competing technology priorities in the company's other geographic regions.

Avoiding duplicative bots

Schneider Electric's RPA team serves as the company's global entry point for software bots.

One of the team's roles is to minimize duplicated effort as requests for bot development roll in from the business side. "So, if we have a call center in Europe put in a request for a use case and another one comes in from the U.S. for something very similar, the global team knows we have already built this," Hackenson said. Without the global team, RPA activity would exist in isolation within business groups, hampering cross-company visibility.

If bots live in silos, "we don't know what is going on and we can't leverage what has been created," she added.

Schneider Electric currently uses RPA software from Blue Prism and UiPath. Hackenson said the platforms are similar, but the company continues to compare them. Thus far, bots have been deployed in customer care centers, finance, HR and supply chain.

Hackenson said she had hoped to have more than 220 software bots in operation by July 1. One issue for the shortfall has been rejected use cases. Schneider Electric's global RPA team, which resides within the company's IT department, reviews RPA use cases submitted from business leaders and has primary responsibility for bot creation. The team has been rejecting more use cases than it accepts, she said.

"We just don't want to automate siloed processes with RPA," Hackenson said. "We want to cut across a process end to end."

We still believe there is a learning curve on RPA.Elizabeth HackensonCIO, Schneider Electric
RPA use cases may also be turned down if the processes they seek to automate are fundamentally broken. And others may fail to offer enough transformative potential.

The RPA team, however, has begun training the business side on appropriate RPA use cases and how best to take advantage of the technology.

"Since we have done the training, we have seen a big increase in use cases now being accepted," Hackenson said. "We still believe there is a learning curve on RPA."

Another issue has been setting expectations for software bot performance. In some cases, the approved RPA use cases have fallen short of the envisioned objective, which has caused the RPA team to pause and revisit some initiatives. She cited one example in which a customer call center bot was expected to take five full-time equivalents (FTEs) off inbound ordering tasks, allowing the employees to pursue higher-value activities. The initial implementation of the bot, however, only freed up two FTEs.

"We are learning it is an iterative process," Hackenson said. The organization had to rethink its labor-reduction expectations and assess whether more tasks needed to be automated to reach the objective, she noted.

Accelerating the RPA journey

The RPA team's goal is to rapidly deliver bots to the business process owners. At this point, bots take about four weeks to develop, but Hackenson said the objective is to shrink that time to two to three weeks.

"We want to move quickly and get it back to the business," she said.

Once the bot arrives on the business side, it generally takes four to eight weeks for process owners to deploy the bot and start realizing its benefits. Hackenson said the RPA team has been exploring the reasons behind the lag. One consideration is the time it takes to transfer FTEs to new assignments.

Hackenson said a change management program is likely to significantly accelerate the pace at which the business side fully uses bots. She would like to see bot acceptance take place within a two-week window.

About Schneider Electric

Smoking Cessation and Nicotine De-addiction Products Market: Precise Analysis on Business Overview, Product Scope and Market Development 2026 | Moderate CAGR of 17.3% Till 2024

Smoking Cessation and Nicotine De-addiction Products Market

The global smoking cessation and nicotine de-addiction products market was valued at US$ 11,285.7 million in 2015 and is expected to witness a moderate CAGR of 17.3% during the forecast period (2016 - 2024).

The Global Smoking Cessation and Nicotine De-addiction Products Market was valued at US$ 11,285.7 million in 2015 and is projected to expand at a CAGR of 17.3% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Rise in awareness regarding the hazardous effects of smoking and nicotine consumption is expected to fuel growth of smoking cessation and nicotine de-addiction products market in the near future.

Have a look on Demo Version: https://www.coherentmarketinsights.com/insight/request-sample/134

Intervention for smoking cessation by the population is an urgent need, as the health hazards due to use of tobacco is increasing globally and is especially prevalent in emerging economies. There are different stages of smoking cessation such as pre-contemplation (the initial thought of quitting), contemplation (when a person decides it is time to quit smoking) and so on. Action is when the attempt is made at least for 24 hours and finally maintenance is when a person is smoke-free for over six months. According to The Indian Journal of Chest Diseases & Allied Sciences, published in 2014, the first-line of treatment part of smoking cessation consists of nicotine replacement therapy, bupropion and varinicline, and clonidine and nortriptalin as a second-line of treatment. Furthermore, in 2014, according to the World Health Organization (WHO), there were around 1,100 million smokers worldwide, which includes around one-third of the global population aged 15 years. The emerging economies accounted for around 70% of the global smoker population. Due to use of tobacco products, around three million deaths occur every year and two-thirds of these are recorded emerging economies. Increasing awareness among the populace is a key factor fueling growth of the smoking cessation and nicotine de-addiction products market over the forecast period. Also, various innovations in the field of drugs and therapies by various companies in the form of various nicotine gums and e-cigarettes is expected to favor growth for smoking cessation and nicotine de-addiction products in the near future. Changing lifestyle leading to high prevalence of anxiety and depression globally is leading to a high number of smokers worldwide, which in turn is expected to support growth in smoking cessation and nicotine de-addiction products in the near future.

To know the latest trends and insights prevalent in the Smoking cessation and nicotine de-addiction products market, click the link below: https://www.coherentmarketinsights.com/market-insight/smoking-cessation-and-nicotine-de-addiction-products-market-134

Government of various economies are taking initiatives to increase awareness among population regarding adverse effects of smoking, which in turn is expected to drive growth of the smoking cessation and nicotine de-addiction products market in the near future. However, lack of funds for tobacco-prevention and cessation programs is a major factor restraining growth of the market. According to Robert Wood Johnson Foundation, in 2007, only three states in the U.S. received funding from Centers for Disease Control and Prevention (CDC), which in turn is negatively affecting growth of the smoking cessation and nicotine de-addiction products market.

According to the American Journal of Preventive Medicine, in 2010, out of 43.4 million smokers in the U.S., around 70% wanted to quit smoking and around 40% made at least one serious quit attempt annually. Therefore, increasing demand for tobacco and smoking cessation products and services creates significant opportunity to reduce tobacco consumption across all age groups. Government of various economies are adopting advanced innovation in the field of smoking cessation products in order to spread awareness among population. For instance, in 2013, German Cancer Research Center, Heidelberg, and the European Commission revised the directive on tobacco products to include e-cigarettes in the tobacco products directive, as such products have been available in Europe since 2006 ,and were very inconsistently regulated across member states. The inclusion of novel products such as e-cigarettes and nicotine gum are projected to favor growth of the smoking cessation and nicotine de-addiction products market over the forecast period.

Key takeaways of the market:

The global smoking cessation and nicotine de-addiction products market is expected to expand at a CAGR of 17.3% during the forecast period (2016–2024). Depression and anxiety globally is expected to favor growth of the smoking cessation and nicotine de-addiction products market over the forecast period.
The E-cigarettes segment in the global smoking cessation and nicotine de-addiction products market was estimated to be the largest in 2015 and is expected to dominate the market throughout the forecast period in terms of value owing to the rise in trend of the novel products among the population.
In terms of E-cigarette sub-segment, the modular E-cigarette type, is expected to expand at a significant CAGR of 19.5% during the forecast period owing to rise in adoption rate by the college students and other chain smokers in the developing countries.
The global smoking cessation and nicotine de-addiction products market is characterized by strategic research and development and advancements in the technology of nicotine and tobacco cessation products and services. Also, the rise in awareness of the effects of smoking in the developing countries is expected to favor the smoking cessation and nicotine de-addiction products market.
Some of the major players are Johnson & Johnson Limited, GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., Cipla Ltd., Takeda Pharmaceuticals Co. Ltd., NJOY, Inc., Imperial Tobacco Company of India Limited, McNeil AB, and Revolymer Limited

To Get Instant Access, Purchase Report Here: https://www.coherentmarketinsights.com/insight/buy-now/134

Detailed Segmentation:

Global Smoking Cessation and Nicotine De-addiction Products Market, By Product Type:

Nicotine Replacement Therapy

- OTC

Nicotine Spray
Nicotine Inhalers
Nicotine Gum
Nicotine Transdermal Patches

- Prescription

Nicotine Sublingual Tablets
Nicotine Lozenges
Drugs

- Varenicline

- Zyban

E-Cigarettes

- Modular

- Disposable

- Rechargeable

Global Smoking Cessation and Nicotine De-addiction Products Market, By Distribution Channel:

Hospital Pharmacies
Online Channel
Retail Pharmacies
Others

Global Smoking Cessation and Nicotine De-addiction Products Market, By Geography:

North America
Europe
Asia-Pacific
Latin America
Middle East
Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Media Contact
Company Name: Coherent Market Insights
Contact Person: Mr. Shah
Email:Send Email
Phone: +1-206-701-6702
Address:1001 4th Ave, #3200
City: Seattle
State: Washington
Country: United States
Website: https://www.coherentmarketinsights.com/insight/buy-now/2619

Neuroendocrine Tumor Treatment Market to Surpass US$ 2.9 Billion by 2025, Underpinned by Increasing Incidence of GI and Lung Neuroendocrine Tumors - Coherent Market Insights

Neuroendocrine Tumor Treatment Market

The global neuroendocrine tumor treatment market was valued at US$ 1,197.3 million in 2015 and is expected to witness a CAGR of 10.5% during the forecast period (2017 - 2025)

The Global Neuroendocrine Tumor Treatment Market was valued at US$ 1,197.3 million in 2016 and is projected to expand at a CAGR of 10.5% during the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Better diagnostic techniques and products in pipeline are expected to be major factors driving growth of the global neuroendocrine tumor treatment market over the foreseeable future.

Neuroendocrine Tumor (NET) are diagnosed more frequently in the U.S. than other countries worldwide. According to U.S. Surveillance Epidemiology and End Results (SEER) Register, in 35 years prior to 2016, the number of GI neuroendocrine tumors/carcinomas of the small intestine has increased 300%-500%, which will drive an ample opportunity for the emerging pharma companies focusing on neuroendocrine tumor treatment drugs. Pulmonary neuroendocrine tumor treatment comprise around 25% of all kinds of neuroendocrine tumor treatment. According to Louisiana State University Health Sciences Center, 2016, Pulmonary Neuroendocrine Tumor Treatment have a low incidence in the U.S., with a rate of 1.6/100,000 individuals. Typical Carcinoid (TC) comprise 1-2% and Atypical Carcinoid (AC) comprise 0.1-0.2% of all pulmonary tumors, whereas small cell lung carcinoma (SCLC) and Large Cell Neuroendocrine Carcinoma (LCNECs) make up 20% and 1.6-3%, respectively

Overall survival is good for the well-differentiated Typical Carcinoid tumors is 92-100% and moderate for AC 61-88%, whereas the higher grade, poorly differentiated SCLC and LCNET have a grim prognosis with OS as low as 5%

To know the latest trends and insights prevalent in the Neuroendocrine Tumor Treatment Market, click the link below: https://www.coherentmarketinsights.com/market-insight/neuroendocrine-tumors-treatment-market-129

According to a report by the American Society of Clinical Oncology in 2014, around 12,000 people are diagnosed with a neuroendocrine tumor and around 1,500 with Merkel cell skin cancer in the U.S., annually. Most of the patients were in the age group 60-65 years, of which around 90% were white people. The survival rate reduces to around 60% when the disease is undiagnosed within the first two years of its occurrence. However, the patients have higher survival rate in neuroendocrine cancer when it is detected in early stages, prior spreading to the lymph nodes or any distant parts of the human body. The GI neuroendocrine tumor is one of the most common indications causing liver metastases, especially when of midgut origin. Furthermore, appendix is the second most common location for midgut carcinoids as it helps to spread cancer to the entire liver.

Around 90 out of 100 people survive for 5 years or more when the carcinoid starts in the appendix. Gastrointestinal neuroendocrine tumors is inherently a diverse group of cells or tumors that sometimes generate various peptides triggering characteristic hormonal disorders. Neuroendocrine tumor treatment can be categorized into clinically symptomatic (functioning) or silent (non-functioning). Both types of NET produce more than one peptide, though these are not associated with specific syndromes.

Key takeaways of the neuroendocrine tumor treatment market:

The global neuroendocrine tumor treatment market is expected to expand at a CAGR of 10.5% during the forecast period (2017–2025) as there exists a huge unrealized market especially in Asia Pacific, Latin America, Middle East and Africa
The Sunitinib Malate and Sufatinib dominates the market in the drug segment, as it is used to treat progressive, well-differentiated advanced and/or metastatic pancreatic neuroendocrine tumors and show a good tolerance in Grade 3 NET patients too.
Gastrointestinal neuroendocrine tumor and pancreatic neuroendocrine tumor are the major indication segment of neuroendocrine tumor treatment market, as these indication are highly prevalent in regions like North America and Asia Pacific
Some of the major players involved in global neuroendocrine tumor treatment market are Pfizer Inc, Novartis AG, Ispen, Advanced Accelerator Applications, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc.and Exelixis, Inc.

Detailed Segmentation:

Global Neuroendocrine Tumor Treatment Market, By Drug:
- Everolimus
- Sunitinib Malate
- Lu-Dotate
- Lanreotide
- Octreotide
Global Neuroendocrine Tumor Treatment Market, By Indication:
- Gastrointestinal NET
- Lung NET
- Pancreatic NET
- Others NET
Global Neuroendocrine Tumor Treatment Market, By End User:
- Hospitals
- Oncology Centers
- Others
Global Neuroendocrine Tumor Treatment Market, By Geography:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East
- Africa
Company Profiles
- Pfizer Inc*
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Key Strategies
  - Recent Developments
  - Future Plans
  - Novartis AG
  - Ispen
  - Advanced Accelerator Applications
  - Tarveda Therapeutics
  - Progenics Pharmaceuticals, Inc.
  - Hutchison Medipharma Limited
  - Dauntless Pharmaceuticals Inc.
  - Exelixis, Inc.

Request For Customization: https://www.coherentmarketinsights.com/insight/request-customization/129

About Coherent Market Insights:

Friday, August 23, 2019

Gaimin.io investigates incorporating human behavioral prediction into machine learning to optimize blockchain mining rewards

Enrique Santos, is welcomed by the Gaimin.io team to be part of the corporate structure in August for his brilliant insights on how human mass psychology and predictable behavioral patterns can help predict crypto market movements and therefore help increase blockchain mining rewards, a fresh and exciting perspective on Gaimin’s machine learning powered mining engine.

Mr. Santos has come up with an idea that he hopes will optimize Gaimin’s rewards gained through blockchain mining. His proprietary intraday trading on currencies and index futures, utilizing systems around technical analysis and stable trading based on human behavior patterns meshed with machine learning will elevate Gaimin’s software platform to reign supreme in this very competitive marketplace.

With more than 18 years of experience in technical analysis, Mr. Santos has so far authored four books, all of which were bought by the Bank of Spain for use by their traders, based on the patterns of Elliott Wave Theory and Fibonacci numbers. These models focus on human psychology and predictable behavioral patterns.

Elliott Wave Theory has been successfully used by top traders and investors to assist in market predictions since the 1930s (https://en.wikipedia.org/wiki/Elliott_wave_principle) when Ralph Nelson Elliott, published his theory of market behavior in the book “The Wave Principle”, and stated that “because man is subject to rhythmical procedure, calculations having to do with his activities can be projected far into the future with a justification and certainty heretofore unattainable.”

Mr. Santos, who comes from Madrid and now resides in Alicante, believes that there is a correlation between Elliott Wave patterns and the price movement of certain mineable cryptos. With this information strategically applied, it is possible to implement parameters that mean a distinct advantage can be gained when compared to the approach traditional crypto miners use.

With the explosive growth of the gaming market in recent years set to continue (https://variety.com/2019/gaming/news/video-games-300-billion-industry-2025-report-1203202672/) and cryptos looking bullish this year, after a difficult 2018, (https://cointelegraph.com/news/crypto-industry-in-numbers-how-does-q2-2019-compare-to-the-past), Gaimin look very well positioned to benefit from the natural upcoming increase in demand for blockchain mining, with their network of gamers and “next generation” blockchain mining solution.

Mr. Santos believes that by adding the secret component of human behavioral prediction into Gaimin’s platform, the “machine learning rules engine” that auto monitors all factors that affect a crypto coins profitability (difficulty, price, depth of market, etc.) and ensures the hash rate is continually directed to the most profitable cryptos will greatly benefit the Gamers earnings.

So far, initial results look very promising, with Santos himself declaring that, “My technique offers a stable analysis and trading method based on human behavior patterns. Cryptos with robust liquidity follow, with a certain degree of accuracy, price movements. These movements can be anticipated with sufficient confidence to be able to substantially increase mining results positively.”

Gaimin.io CEO Martin Speight stated: “it’s important to understand the power of compounding incremental increases in performance. It’s because of this we have been able to produce the superior results which can be read in our Whitepaper and Alpha Test results. Our partnership with Enrique Santos reflects our ongoing commitment to help gamers achieve maximum monetization of their GPU when using our platform.”

From Gaimin’s initial successful alpha test results, with 100 users in 12 countries, each mining only 4 hours each day, a user was rewarded with $1 per day, achieved targeted KPI. This figure was a starting point for Gaimin’s platform, on which they look forward to increasing and giving a greater return to the gaming community.

About Gaimin:

The Gaimin platform is a powerful yet elegant AI-driven software that aggregates a gamer’s processing power, when not being used and therefore without affecting their gaming performance, to the Gaimin monetization network. In exchange for this the gamer receives purchasing power via the GMRX crypto token, which can be spent directly on gaming purchases. Gamers can now passively monetize their powerful PC resources without the need for any specialized knowledge or action.

Media Contact
Company Name: Blockcast.cc
Contact Person: Joann Park
Email:Send Email
Phone: +65 98832707
Country: Singapore
Website: https://www.blockcast.cc

Protein Cookie Market Will Generate Massive Revenue In Future - A Comprehensive Study On Leading Players

Protein Cookie Market

The global protein cookie market is expected to be valued at US$ 42.54 billion by 2027, and is expected to register a CAGR of 5.15% in terms of revenue over the forecast period (2019 - 2027).

The global protein cookie market was valued at US$ 27.16 Bn in 2018, according to Protein Cookie Market Report, by Flavor (Fruit & Dried Fruits, Chocolate, Nuts & Seeds, and Others (Spices, Oatmeal, etc.)), by Protein Source (Plant Source and Animal Source), by Distribution Channel (Hypermarkets & Supermarkets, Convenience Stores, Online Stores, and Others (Grocery Stores, Departmental Stores, etc.)), and by Region (North America, Latin America, Asia Pacific, Europe, and Middle East & Africa) published by Coherent Market Insights.

The global protein cookie market is projected to reach US$ 42.54 Bn by 2027, exhibiting a CAGR of 5.15% during the forecast period (2019-2027). Cookies are one of the most preferred products of the bakery industry. Cookies that contain protein supplements offer health benefits such as muscle strengthening, which is expected to fuel demand for protein cookies during the forecast period.

Get The Holistic SAMPLE With Research Methodology: https://www.coherentmarketinsights.com/insight/request-sample/2599

According to sector trend analysis of bakery products published by Agricultural and Agri-food department of Canada in December 2016, the worldwide bakery market in terms of retail value reached to US$ 338.7 billion in 2015 from US$ 321.8 billion in 2014 with a CAGR of 4.7% from 2010 to 2015. Therefore, growing bakery industry is expected to propel demand for protein cookies over the forecast period.

Key Trends and Analysis of the Protein Cookie Market:

Key players operating in the protein cookie products market are focused on launching new products in order to enhance their market share. For instance, in November 2018, Hershey India Private Ltd. launched a new protein cookie product, with a brand name ‘Sofit Protein Cookies’. These protein cookies contain proteins along with omega-3, fibers, and vitamins and are offered in different flavors such as mango, cocoa, and resins.

Request Customization Of Research Report: https://www.coherentmarketinsights.com/insight/request-customization/2599

Browse 24 market data tables* and 12 figures* on "Protein Cookie Market” - Global forecast to 2027.

Key Takeaways of the Market:

Among flavors, the chocolate segment accounted for a significant market share in the protein cookie market in 2018, owing to sweet aroma, taste, and high nutritional contents of chocolate. Increasing cocoa production is expected to boost growth of the segment over the forecast period. For instance, according to Quarterly Bulletin of Cocoa Statistics published by International Cocoa Organization in August 2018, worldwide production of cocoa beans was 3997 thousand tons in crop year 2015 – 2016, which increased to 4730 thousand tons in crop year 2016 – 2017.

Among protein source, the plant source segment is expected to witness significant growth during the forecast period. This is owing to increasing awareness regarding health benefits offered by plant-based ingredients. Plant-based protein sources include, soy, rice bran, and pea. Major players in the market are focused on offering cookies that contain plant-based protein. For instance, Justine’s Limited offers Justine’s protein cookies, which contain soy protein isolate. These cookies are available in various flavors such as chocolate chips, raspberry, and peanut butter.

Among regions, Europe is expected to account for significant market share over the forecast period, owing to growing bakery industry in the region. According to Sector Trend Analysis – Dough Products, published by Agriculture and Agri-Food Department of Government of Canada, November 2017, Europe is the most dynamic region for value-added bakery products and during 2007 to 2016, the region launched the highest number of dough products in the world and experienced the highest retail sales for bakery products in the world. The report also stated that the global bakery retail sale was US$ 326,564.6 Mn, of which Europe accounted for US$ 123,205.8 Mn, in 2016.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/2599

Major players operating in the global protein cookie market include, Lenny & Larry's LLC, Quest Nutrition, The Hershey Company, Munk Pack, Justine’s Limited, NuGo Nutrition, No Cow LLC, Buff Bake, MuscleTech, and Xterra Nutrition

About Coherent Market Insights:

Short Bowel Syndrome Market Recent Developments, Expansion Plans, Mergers & Acquisitions

Short Bowel Syndrome

The main causes of short bowel syndrome in children is damaged intestinal tissue, blockage or obstruction in intestine, gastroschisis, and rotation of the midgut also known as malrotation and in grown-ups.

Short bowel syndrome (SBS) is a malabsorption syndrome caused as a result of the small intestine not functioning efficiently. One of the prime symptoms of short bowel syndrome is diarrhea, which leads to dehydration, malnutrition, and unexplained and drastic weight loss in most the patients. If left untreated, SBS can lead to complication such as anemia and kidney stones. The main causes of short bowel syndrome in children is damaged intestinal tissue, blockage or obstruction in intestine, gastroschisis, and rotation of the midgut also known as malrotation and in grown-ups. Short bowel syndrome is detected in Crohn’s disease, radiation enteritis, and mesenteric ischemia. This syndrome usually occurs in cases due to surgical elimination of major portion of small intestine

Significant healthcare burden due to short bowel syndrome, especially in low-income countries

According to Crohn’s & Colitis Foundation of America, in 2010 there were 10,000–20,000 people in the reported cases of short bowel syndrome, out of which 25% people suffer some or the other complication within two years of contracting the condition. The rate of absorption decreases and due of lack of sufficient nutrients to the body, many children die due to malnutrition. According to Sancilio and Company, Inc, most cases of short bowel syndrome are due to birth in congenital anomaly, in which there occurs a rotation of midgut and the child die before the age of 6 years. According to Nutrinia Ltd, the existing approach to treat infants suffering from short bowel syndrome includes proper nutritional, pharmacologic, and surgical interventions. The objective is to endorse enteral nutrition, while curtailing the difficulties of parenteral nutrition therapy. Most of the patients are given long-term parenteral treatment, which affects the patient and significantly increases the chances of liver disease, infections, and other complications. Babies who have substantial short bowel syndrome frequently struggle from intestinal failure-associated liver disease, bloodstream infections, and bacterial overgrowth. Furthermore, parenteral nutrition leads to a substantial economic burden on the general population and the healthcare system, with overall annual costs ranging from an estimated US$ 180,000 to US$ 570,000 and more.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/169

GLP-2 drug class dominates the leading markets in North America and Europe

The global short bowel syndrome market is segmented on the basis of drug class and geography. On the basis of drug class, the market is divided into GLP-2, growth hormone, glutamine and others.

Increasing prescription of Gattex Therapy for Short Bowel Syndrome in North America creates a highly lucrative prospect for growth

Regional segmentation of the short bowel syndrome market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounts for the largest share in global market, mainly due to presence of major players and early adoption of advanced medical technologies in countries such as the U.S. and Canada. According to National Institute of Diabetes and Digestive and Kidney Disease, in 2008, there were more than 2,000 intestinal transplantations performed in the U.S., out of which 75% population was of the age group of 18-20 years. These numbers are expected to increase year on year, which would inadvertently fuel growth of the short bowel syndrome market.

Key players in the global short bowel syndrome market

Key players operating the short bowel syndrome market include Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc., Merck KGaA, Naia Pharmaceuticals, Inc., Nutrinia Ltd., OxThera, Sancilio & Company, Inc., Shire plc, and Zealand Pharma A/S. Major companies in the short bowel syndrome industry are constantly working towards introducing innovative products and lowering production costs in order to enhance profitability. For instance, Nutrinia Ltd. plans to begin a critical clinical trial on a drug for short bowel syndrome, which will aid thousands of patients globally by reducing their dependence on parenteral nutrition is the major cause of liver infection.

Purchase a copy of report @https://www.coherentmarketinsights.com/insight/buy-now/169

About Us: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Vitiligo Drugs Market Analysis by Latest Trends, Growth in Manufacturing

Vitiligo Drugs

The global vitiligo drugs market size was valued at US$ 120.6 million in 2017, and is expected to exhibit a CAGR of 8.4% over the forecast period (2018-2026).

Vitiligo is a skin condition characterized by white patches on the skin. It is also known as skin depigmentation. In skin depigmentation, the skin's pigment-making cells known as melanocytes are lost or destroyed, which result into patches. The patches of affected skin appear white and usually have sharp margins. In most of the cases, the patches emerge on the skin, which is more exposed to sunlight. Although the disease can occur at any age, it is more observed in the mid-twenties. Although the disease does not affect the physical health of a person, it creates concerns about physical appearance and ethical identity of the person. The exact cause of vitiligo is not known. It is mostly observed in people with family history of autoimmune diseases.

The global vitiligo drugs market size was valued at US$ 120.6 million in 2017, and is expected to exhibit a CAGR of 8.4% over the forecast period (2018–2026).

Vitiligo causes loss of skin color in spots. It can affect the skin on any part of the body, hair, and the inside of the mouth. Treatment for vitiligo can restore the color to the affected spot on the skin. However, it cannot completely prevent skin discoloration. According to the American Academy of Dermatology, 2017, the prevalence of vitiligo is approximately 1% in the U.S. and Europe.

Vitiligo is listed among 24 skin diseases examined in the Burden of Skin Disease report commissioned by the American Academy of Dermatology. Moreover, according to reports published by the American Academy of Dermatology in 2017, over 150,000 patient were treated for vitiligo during 2013 in the U.S. According to a study published in the National Center for Biotechnology Information (NCBI), in October 2017, an estimated 0.5-1% of the global population was diagnosed with vitiligo. Furthermore, in the same year, approximately 8.8% of India’s population and 0.38% of Denmark’s population was diagnosed with vitiligo.

Get Sample Copy of Professional Insights: https://www.coherentmarketinsights.com/insight/request-sample/2447

Therefore, increasing worldwide prevalence of vitiligo is expected to aid in growth of the global vitiligo drugs market over the forecast period.

However, availability of advanced technologies and alternative therapies for vitiligo treatment is expected to restrain growth of the vitiligo drugs market during the forecast period. For instance, in October 2018, STRATA Skin Sciences, a manufacturer of innovative products for the treatment of skin conditions, announced the launch of XTRAC S3 308nm Laser at the American Society for Dermatologic Surgery Meeting. The XTRAC S3 308nm Laser is used for the treatment of skin disorders such as psoriasis and vitiligo. The XTRAC laser utilizes therapeutic UVB light for the treatment of affected skin areas without damaging surrounding healthy skin.

Increasing number of initiatives undertaken by various government organizations to develop novel treatments for vitiligo is expected to augment the market growth. For instance, in February 2019, American Skin Association (ASA) announced funding for 18 new grants for skin cancer and disease research. The ASA and its affiliates invested over US$ 50 Mn for the treatment of melanoma, psoriasis, and vitiligo. Moreover, various government organizations are also focused on offering funds to accelerate development of effective treatment options for vitiligo, thereby augmenting the market growth. For instance, the Vitiligo Society in Europe funds research projects with the aim of establishing the real causes of vitiligo as well as developing effective and safe treatments for patients. The Society also supports and closely monitors research initiatives and is supported by a Medical and Scientific Advisory Panel.

Key Players

Key players in the market are focused on adopting acquisition strategies to enhance their market share, which is expected to augment the market growth. For instance, in 2017, Aclaris Therapeutics, Inc. acquired Confluence Life Sciences, Inc., a company focused on development of kinase inhibitors for the treatment of autoimmune disorders such as alopecia areata, vitiligo, and atopic dermatitis.

Major players operating in the global vitiligo drugs market include, Dermavant Sciences, Inc., Incyte Corporation, Aclaris Therapeutics, Inc., Dr. Reddy’s Laboratories Ltd., Bristol - Myers Squibb, Pfizer, Inc., Clinuvel Pharmaceuticals Ltd., Applied Biology, Inc., and Boston Pharmaceuticals.

Purchase a copy of report @https://www.coherentmarketinsights.com/insight/buy-now/2447

At 4.9%% CAGR, Enteral Syringe Market to Surpass US$ 885 Million USD by 2026

Enteral syringes are majorly used for administering drugs

Enteral syringes assists in precise measurement of medicines. These syringes are available in purple plunger in order to distinguish them from other types of syringes.

Regulatory guidelines for design and manufacturing of enteral devices including enteral syringe were recently updated by various regulatory bodies. In 2015, new design standards were introduced in enteral feeding sets, enteral syringes, and enteral feeding tubes referred as ENFit. ENFit is a new connection standard that is developed by an international group of clinicians, manufacturers body Global Enteral Device Supplier Association (GEDSA), and regulators under aegis of Stay Connected initiative to prevent tubing misconnections and patient injury. Tubing misconnection occurs when enteral devices are connected to non-enteral devices such as IV lines, urinary catheters, and ventilator tubing.

Global Enteral Device Supplier Association (GEDSA) promotes safe use of enteral devices including syringes. Market players that comply with ENFit standard design are receiving 510(k) clearance from the U.S Food and Drug Administration (U.S. FDA). For instance, in 2016, NeoMed and Medtronic received the U.S FDA 510(k) clearance for low dose tip ENFit syringes. NeoMed has offered royalty-free access of its design to all syringe manufacturers. Therefore, several manufacturers can implement this design standard to promote safe use of these devices, which in turn is expected to increase adoption of enteral syringes.

Request Sample Copy of this Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2398

Market Dynamics

Major factor driving growth of the enteral syringe market is increasing prevalence of chronic diseases such as cancer, which often results in hospital admissions in late stage of the disease. These patients are unable to ingest any kind of food and medicines, therefore, enteral syringes are preferred in such situations. According to a report by International Agency for Research on Cancer, titled GLOBOSCAN, September 2018, around 18.1 million new cancer cases and 9.6 million cancer deaths were recorded in 2018, worldwide.

Moreover, same source mentions that, one out of every five men and one out of every six women worldwide suffer from cancer during their lifetime and one out of every eight men and one out of every 11 women die from the disease. The total number of people surviving within 5 years of a cancer diagnosis, called the 5-year prevalence, is around 43.8 million, worldwide. Another major factor for growth of this market is changed syringe design adopted internationally which ensures extra safety and allows wider use of enteral syringe devices worldwide. In the year 2018, several manufacturers launched ENFit compliant enteral syringe in the market which would help in expansion of the market

Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2398

Detailed Segmentation:

Global Enteral Syringe Market, By Product Type:

Single Use Enteral Syringes

Home Use Enteral Syringes

Catheter Tip Syringes

Others

Global Enteral Syringe Market, By Application:

Cancer

Malnutrition

Neurological Disease

GI Related Disease

Others

Global Enteral Syringe Market, By Patient Group:

Neonates and Pediatrics

Adults

Global Enteral Syringe Market, By End User:

Hospitals and Ambulatory care centers

Home-based user

Key players operating in the global enteral syringe market include, B. Braun Melsungen AG, GBUK Enteral Ltd., Thermo Fischer, Inc., Koninklijke Philips N.V., Miktell Ltd., Baxter International, Inc., Cardinal Health, Inc., Terumo Corporation, Kentec Medical, Inc., Vygon S.A., and others.

Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2398

About Us:

Media Contact
Company Name: Coherent Market Insights
Contact Person: Mr. Shah
Email:Send Email
Phone: +1-206-701-6702
Address:1001 4th Ave, #3200
City: Seattle
State: Washington
Country: United States
Website: www.coherentmarketinsights.com/market-insight/enteral-syringe-market-2398